Ras-AKT signaling represses the phosphorylation of histone H1.5 at threonine 10 via GSK3 to promote the progression of glioma

References

• Zeng T, Cui D, Gao L. Glioma: an overview of current classifications, characteristics, molecular biology and target therapies. Front Biosci. 2015; 20:1104–1115.
   PubMed Web of Science ®Google Scholar
• Konar SK, Bir SC, Maiti TK, et al. A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord. J Neurosurg Pediatr. 2017;19:239–248.
   PubMed Web of Science ®Google Scholar
• Luhtala N, Aslanian A, Yates JR, III, et al. Secreted glioblastoma nanovesicles contain intracellular signaling proteins and active Ras incorporated in a farnesylation-dependent manner. J Biol Chem. 2017;292:611–628.
   PubMed Web of Science ®Google Scholar
• Holmen SL, Williams BO. Essential role for Ras signaling in glioblastoma maintenance. Cancer Res. 2005;65:8250–8255.
   PubMed Web of Science ®Google Scholar
• Niu W, Wang G, Feng J, et al. Correlation between microsatellite instability and RAS gene mutation and stage III colorectal cancer. Oncol Lett. 2019; 17:332–338.
   PubMed Web of Science ®Google Scholar
• Wei L, Chang H, Huo S. Analyses on K-ras mutations and fascin expression in patients with cardia cancer. Oncol Lett. 2019;17:1807–1811.
   PubMed Web of Science ®Google Scholar
• Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287–1292.
   PubMed Web of Science ®Google Scholar
• Coura BP, Bernardes VF, de Sousa SF, et al. KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features. Mod Pathol. 2019;32:799–806.
   PubMed Web of Science ®Google Scholar
• Polosukhina D, Love HD, Correa H, et al. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol. 2017;11:405–421.
   PubMed Web of Science ®Google Scholar
• Kimura H. Histone modifications for human epigenome analysis. J Hum Genet. 2013;58:439–445.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zheng H, Huang B, et al. Allelic reprogramming of the histone modification H3K4me3 in early mammalian development. Nature. 2016;537:553–557.
   PubMed Web of Science ®Google Scholar
• Nammo T, Udagawa H, Funahashi N, et al. Genome-wide profiling of histone H3K27 acetylation featured fatty acid signalling in pancreatic beta cells in diet-induced obesity in mice. Diabetologia. 2018;61:2608–2620.
   PubMed Web of Science ®Google Scholar
• Khachaturov V, Xiao GQ, Kinoshita Y, et al. Histone H1.5, a novel prostatic cancer marker: an immunohistochemical study. Hum Pathol. 2014;45:2115–2119.
   PubMed Web of Science ®Google Scholar
• Momeni M, Kalir T, Farag S, et al. Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report. Cell Oncol. 2014;37:229–234.
   Web of Science ®Google Scholar
• Momeni M, Kalir T, Farag S, et al. Immunohistochemical detection of promyelocytic leukemia zinc finger and histone 1.5 in uterine leiomyosarcoma and leiomyoma. Reprod Sci. 2014;21:1171–1176.
   PubMed Web of Science ®Google Scholar
• Pan XW, Zhao XH. In vitro proliferation and anti-apoptosis of the papain-generated casein and soy protein hydrolysates towards osteoblastic cells (hFOB1.19). Int J Mol Sci. 2015;16:13908–13920.
   PubMed Web of Science ®Google Scholar
• Happel N, Stoldt S, Schmidt B, et al. M phase-specific phosphorylation of histone H1.5 at threonine 10 by GSK-3. J Mol Biol. 2009;386:339–350.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xing ZB, Zhang JH, et al. Akt kinase targets the association of CBP with histone H3 to regulate the acetylation of lysine K18. FEBS Lett. 2013;587:847–853.
   PubMed Web of Science ®Google Scholar
• Steinbrunn T, Stuhmer T, Gattenlohner S, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood. 2011;117:1998–2004.
   PubMed Web of Science ®Google Scholar
• Nihira NT, Ogura K, Shimizu K. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. Sci Signal. 2017;10:pii: eaai8026.
   Web of Science ®Google Scholar
• Godde JS, Ura K. Cracking the enigmatic linker histone code. J Biochem. 2007;143:287–293.
   Web of Science ®Google Scholar
• Liao R, Mizzen CA. Interphase H1 phosphorylation: regulation and functions in chromatin. Biochim Biophys Acta. 2016;1859:476–485.
   PubMed Web of Science ®Google Scholar
• Fang B. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochim Biophys Sin (Shanghai). 2016;48:27–38.
   PubMed Web of Science ®Google Scholar
• Sun ZJ, Wang Y, Cai Z, et al. Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer. 2008;99:1656–1667.
   PubMed Web of Science ®Google Scholar
• Habel N, Stefanovska B, Carene D, et al. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rbeta-dependent EMT-like process. BMC Cancer. 2019;19:62.
   PubMed Web of Science ®Google Scholar
• Johnson LM, Price DK, Figg WD. Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment. Cancer Biol Ther. 2013;14:90–91.
   PubMed Web of Science ®Google Scholar
• Chen CH, Chen PY, Lin YY, et al. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma. J Neurosurg. 2019; 1–12. [Epub ahead of print]. doi:10.3171/2018.8.JNS181217
   Web of Science ®Google Scholar
• Peng D, Hu Z, Wei X, et al. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3beta signaling pathway in renal cell cancer. IUBMB Life. 2019;71:113–124.
   PubMed Web of Science ®Google Scholar
• Lu X, He X, Su J, et al. EZH2-mediated epigenetic suppression of GDF15 predicts a poor prognosis and regulates cell proliferation in non-small-cell lung cancer. Mol Ther Nucleic Acids. 2018; 12:309–318.
   PubMedGoogle Scholar
• Karasawa T, Kawashima A, Usui F, et al. Oligomerized CARD16 promotes caspase-1 assembly and IL-1beta processing. FEBS Open Biol. 2015;5:348–356.
   PubMed Web of Science ®Google Scholar
• Paudel P, Seong SH, Zhou Y, et al. Rosmarinic acid derivatives' inhibition of glycogen synthase kinase-3beta is the pharmacological basis of Kangen-Karyu in Alzheimer's disease. Molecules. 2018;23;pii: E2919.
   Web of Science ®Google Scholar
• Lee SK, Jeong WJ, Cho YH, et al. Beta-catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3beta. EMBO Rep. 2018;19:pii: e46060.
   Web of Science ®Google Scholar
• Kazi A, Xiang S, Yang H, et al. GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors. Nat Commun. 2018;9:5154.
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.
   PubMedGoogle Scholar
• Colon-Otero G, Weroha SJ, Foster NR, et al. Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol. 2017;146:64–68.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun D, Sun W, et al. Ras-PI3K-AKT signaling promotes the occurrence and development of uveal melanoma by downregulating H3K56ac expression. J Cell Physiol. 2019. [Epub ahead of print]. doi:10.1002/jcp.28261
   Web of Science ®Google Scholar
• Liu Y, Wang DL, Chen S, et al. Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56. J Biol Chem. 2012; 287:41469–41480.
   PubMed Web of Science ®Google Scholar